CN113384644A - 一种中药组合物及其制备方法 - Google Patents
一种中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN113384644A CN113384644A CN202110865627.3A CN202110865627A CN113384644A CN 113384644 A CN113384644 A CN 113384644A CN 202110865627 A CN202110865627 A CN 202110865627A CN 113384644 A CN113384644 A CN 113384644A
- Authority
- CN
- China
- Prior art keywords
- parts
- fructus
- radix
- extracting
- raw materials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 33
- 239000002994 raw material Substances 0.000 claims abstract description 17
- 235000000832 Ayote Nutrition 0.000 claims abstract description 15
- 235000009854 Cucurbita moschata Nutrition 0.000 claims abstract description 15
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 claims abstract description 15
- 235000015136 pumpkin Nutrition 0.000 claims abstract description 15
- 229940076130 chromium gluconate Drugs 0.000 claims abstract description 14
- ANPGUZATXCGJJH-OPDGVEILSA-K chromium(3+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Cr+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O ANPGUZATXCGJJH-OPDGVEILSA-K 0.000 claims abstract description 14
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 13
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 13
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 13
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 13
- 244000268590 Euryale ferox Species 0.000 claims abstract description 12
- 235000006487 Euryale ferox Nutrition 0.000 claims abstract description 12
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 11
- 235000006533 astragalus Nutrition 0.000 claims abstract description 10
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 9
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 8
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 8
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 8
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 8
- 235000011477 liquorice Nutrition 0.000 claims abstract description 8
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 7
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 7
- 241001061264 Astragalus Species 0.000 claims abstract description 6
- 210000004233 talus Anatomy 0.000 claims abstract description 6
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 5
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims description 33
- 240000001980 Cucurbita pepo Species 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 241000229143 Hippophae Species 0.000 claims description 11
- 235000013399 edible fruits Nutrition 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 210000000582 semen Anatomy 0.000 claims description 8
- 238000007873 sieving Methods 0.000 claims description 8
- 239000009636 Huang Qi Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 235000003935 Hippophae Nutrition 0.000 claims description 5
- 241000045403 Astragalus propinquus Species 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 210000002421 cell wall Anatomy 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 38
- 239000008280 blood Substances 0.000 abstract description 38
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 18
- 239000008103 glucose Substances 0.000 abstract description 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 16
- 102000004877 Insulin Human genes 0.000 abstract description 8
- 108090001061 Insulin Proteins 0.000 abstract description 8
- 229940125396 insulin Drugs 0.000 abstract description 8
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 108010081690 Pertussis Toxin Proteins 0.000 abstract description 3
- 230000004087 circulation Effects 0.000 abstract description 3
- 230000002093 peripheral effect Effects 0.000 abstract description 3
- 210000001519 tissue Anatomy 0.000 abstract description 3
- 229920002527 Glycogen Polymers 0.000 abstract description 2
- 230000004153 glucose metabolism Effects 0.000 abstract description 2
- 229940096919 glycogen Drugs 0.000 abstract description 2
- 230000001965 increasing effect Effects 0.000 abstract description 2
- 230000008929 regeneration Effects 0.000 abstract description 2
- 238000011069 regeneration method Methods 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 230000028327 secretion Effects 0.000 abstract description 2
- 240000004244 Cucurbita moschata Species 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 20
- 206010012601 diabetes mellitus Diseases 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 12
- 210000003734 kidney Anatomy 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 11
- 210000002700 urine Anatomy 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 206010036067 polydipsia Diseases 0.000 description 5
- 230000035922 thirst Effects 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 206010006895 Cachexia Diseases 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000026500 emaciation Diseases 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 239000010871 livestock manure Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 206010020710 Hyperphagia Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000002398 materia medica Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 208000022530 polyphagia Diseases 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229940107666 astragalus root Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000013824 Acidemia Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004226 retinal microvascular lesions Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种能够改善并发症和调节血糖的中药组合物及其制备方法,组合物原料包括黄芪、山药、西洋参、南瓜粉、乌梅、葛根、芡实、沙棘、五味子、酸枣仁、甘草、葡萄糖酸铬,所制备的中药组合物富含胰岛活化因子,它可促进胰岛β细胞修和再生,改善胰岛功能,从而增加内源性胰岛素的分泌,加强外周组织对葡萄糖的利用,促进糖元的合成,使血糖降低—糖代谢进入正常循环,而且内源性胰岛素同时可以促进脂肪合成,抑制脂肪分解。
Description
技术领域
本发明涉及中药组合物技术领域,更具体的说是涉及一种中药组合物及其制备方法。
背景技术
糖尿病是一种内分泌代谢疾病,而以高血糖为其共同主要标志。因胰岛素分泌绝对或相对不足以及β细胞对胰岛素敏感性降低,引起糖、蛋白质、脂肪、和继发的水、电解质紊乱。临床主要表现烦渴、多尿、多饮、多食、疲乏、消瘦等。然而,相当一部分甚至多数病并无上述症状,仅于全面体查或出现合并症才被发现。糖尿病严重时可发生酮症酸中毒或其它类型急性代谢紊乱。常见的合并症有急性感染、肺结核、动脉粥样硬化、肾和视网膜微血管病变及神经病变等。
目前,我国生产的糖尿病用药大约几十种,按药物的化学结构与作用原理,把降糖药分为胰岛素、双胍类、磺脲类、中药制剂。
(1)胰岛素主要用于I型糖尿病,虽疗效可靠,但剂型单一(只有针剂),价格昂贵,长期使用会产生胰岛素抵抗,疗效降低,停药后症状立即反弹,且易出现低血糖、过敏等不良反应,使用时既痛苦又不方便(肌肉注射);
(2)双弧类主要增加周围组织对葡萄糖的利用和抑制胃肠道对萄萄糖的吸收,治疗对象为Ⅱ型糖尿病,易导致胃肠道反应、乳酸血症和营养不良,许多国家已停止使用,我国临床尚有一定应用;
(3)磺脲类降血糖较慢。在肝脏随胆汁经肾脏排出,长期服用易产生耐药性且损害肝肾;
(4)餐食血糖调节剂,a葡萄糖甘醇抑制剂效果不明显,应用较少。
因此,如何提供一种滋补肝肾、益气生津。用于多饮、多尿、多食、消瘦、体倦乏力、腰膝酸软、血糖、尿糖升高以及改善并发症和调节血糖的中药组合物及其制备方法是本领域技术人员亟需解决的技术问题。
发明内容
有鉴于此,本发明的目的在于提供一种用于改善并发症和调节血糖的中药组合物及其制备方法,所制备的中药组合物富含胰岛活化因子,它可促进胰岛β细胞修和再生,改善胰岛功能,从而增加内源性胰岛素的分泌,加强外周组织对葡萄糖的利用,促进糖元的合成,使血糖降低—糖代谢进入正常循环,而且内源性胰岛素同时可以促进脂肪合成,抑制脂肪分解。
为了实现上述目的,本发明采用如下技术方案:
一种中药组合物,包括以下重量份的原料:
黄芪32-48份、山药32-48份、西洋参20-30份、南瓜粉20-30份、乌梅20-30份、葛根16-24份、芡实16-24份、沙棘16-24份、五味子16-24份、酸枣仁16-24份、甘草5-9份、葡萄糖酸铬0.04-0.06份。
进一步的,上述的中药组合物,包括以下重量份的原料:
黄芪40份、山药40份、西洋参25份、南瓜粉25份、乌梅25份、葛根20份、芡实20份、沙棘20份、五味子20份、酸枣仁20份、甘草7份、葡萄糖酸铬0.05份。
一种中药组合物的制备方法,包括以下步骤:
(1)称取上述各原料,备用;
(2)将各原料洗净、去除杂质,在66-70℃下干燥;
(3)将南瓜粉、酸枣仁、芡实、五味子和甘草破壁处理,过筛,得细粉A;
(4)将葛根、黄芪、山药、乌梅、沙棘和西洋参混合,然后提取,制膏干燥后,粉碎,过筛,得细粉B;
(5)将细粉A、细粉B和葡萄糖酸铬混合均匀,按所需剂型制得成品。
优选的,步骤(3)中所述破壁处理采用破壁机,转速为40000~45000r/min;时间1~2min。
优选的,步骤(4)中所述提取为将葛根、黄芪、山药、乌梅、沙棘和西洋参放入多功能提取罐中,加11倍量水回流提取2.5-3h,药渣加9倍水回流提取1.5-2h,得提取液。
优选的,步骤(4)中制膏为将所述提取液经离心机滤过,减压浓缩至在70℃下测定相对密度为1.32-1.34的稠膏,之后在80-85℃条件下干燥。
本发明中原料组合物的药用机理为:
方中以黄芪、山药为君,其中黄芪味甘,性微温,入肺脾经,能补中益气。《名医别录》云:其“补丈夫虚损,五劳嬴瘦止渴,腹痛、泻痢、益气、利阴气”。《医学衷中参西录》又云:“黄芪能大补肺气,以益肾水之上源,使气旺自能生水"。山药味甘性平,入肺,睥,肾经,既能补肾益阳,又能健脾补肾,《本草正》云:“山药,能健脾补虚,滋精固肾,治诸虚百损,疗五劳七伤”。《医学衷中参西录》云:“有单服山药以治消渴而愈者。以其能补脾固肾,以止小便频数……且色白入肺,能润肺生水,即以止渴也”,“拟以玉液汤,方中以生怀山药为主,屡试有效"。黄芪与山药相伍。非但脾肾并补,而且可以补气益阴;
方中以西洋参、南瓜粉为臣药,西洋参味甘微苦、性谅。《医学衷中参西录》云其:“能补助气分,兼能补助血分”,为其性凉而补。南瓜味甘性温,能补中益气,《滇南本草》称其“横行旧了经络利小便。”此二药合而用之,可增强君药固肾滋阴,补脾益气之功;
方中佐以葛根,取其味甘性平,《本草正义》云其:“最能生发脾胃清阳之气,入脾胃生发脾胃清阳而转输津液,使津液四布,则口渴自止。乌梅味酸,性微温,能敛津止渴,《本草拾遗》谓其“祛痰,止渴,收汁”。酸枣仁味酸,性平,养肝,宁心安神,敛汗。《名医别录》云其:“主烦心不得眠,脐上下痛,血转久泄,虚汗烦渴,补中,益肝气,坚筋骨,助阴气,令人肥健。此三味相伍,可助山药补脾胃,以滋阴精,以敛阴津;
南瓜性温,味甘,可补中益气,能防治多种疾病,通过临床证明:服用南瓜粉后,健康人和非胰岛素依赖型糖尿病患者的70%~90%发生血糖降低现象,非胰岛素依赖型患者服用南瓜粉以后,饥饿感消失,南瓜粉的降血糖作用高于升胰岛素作用,因此南瓜粉是糖尿病人优质的保健食品。
本发明在组合物中辅以葡萄糖酸铬,缺三价铬现象严重的地区糖尿病的发病率高,通过三价铬的补充,能有效地控制糖尿病,消除葡萄糖耐量方面的异常现象。
经由上述的技术方案可知,与现有技术相比,本发明的有益效果如下:
(1)本发明提供的组合物中诸成份属药食同源,所谓药食同源是指成份既是食品又是药品,药食兼备。长期服用无毒副作阳、安全性强;
(2)本发明提供的组合物不仅能从根本上治疗糖尿病及并发症而对有类似糖屎病症状的非健康人群具有保健作用,去具有双重的疗效。药用机理是对糖尿病的病因——胰岛分泌不足及靶细胞的敏感性降低去对因治疗,组合物中富含胰岛活化因子,可促进胰岛β细胞中胰岛素受体的敏感性,促使糖代谢和脂肪代射进入正常循环,其较强的活血化瘀作用,能抑制血小板的凝集,改善血液的粘稠积聚状态,增强血管弹性,降低其通透性,有明显的降血糖、降血压、改善症状及自身调解作用,本发明还含有多种微量元素,尤其合成胰岛细胞必须的锌、铬和钴,又有较好的保健作用;
(3)本发明提供的中药组合物具有较强的活血化瘀作用,能改善血液的粘稠积聚状念,并能增强血管弹性,降低其通透性,因而对糖尿病或其它不明原因引起的心、脑、肾、眼等脏器的并发症有根本的疗效。
具体实施方式
下面对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
一种用于改善并发症和调节血糖的中药组合物,包括以下重量份的原料:
黄芪48g、山药48g、西洋参30g、南瓜粉30g、乌梅30g、葛根24g、芡实24g、沙棘24g、五味子24g、酸枣仁24g、甘草9g、葡萄糖酸铬0.06g。
实施例2
一种中药组合物,包括以下重量份的原料:
黄芪32g、山药32g、西洋参20g、南瓜粉20g、乌梅20g、葛根16g、芡实16g、沙棘16g、五味子16g、酸枣仁16g、甘草5g、葡萄糖酸铬0.04g。
实施例3
一种中药组合物,包括以下重量份的原料:
黄芪40g、山药40g、西洋参25g、南瓜粉25g、乌梅25g、葛根20g、芡实20g、沙棘20g、五味子20g、酸枣仁20g、甘草7g、葡萄糖酸铬0.05g。
实施例4
实施例1-3任一所述的一种中药组合物的制备方法,包括以下步骤:
(1)称取各原料,备用;
(2)将各原料洗净、去除杂质,在70℃下干燥;
(3)将南瓜粉、酸枣仁、芡实、五味子和甘草放入破壁机中,在45000r/min的转速下破壁1min,过100目筛,得细粉A;
(4)将葛根、黄芪、山药、乌梅、沙棘和西洋参放入多功能提取罐中,加11倍量水回流提取3h,药渣加9倍水回流提取2h,得提取液,然后将提取液经离心机滤过,减压浓缩至在70℃下测定相对密度为1.34的稠膏,在80℃下干燥后,粉碎,过100目筛,得细粉B;
(5)将细粉A、细粉B和葡萄糖酸铬混合均匀,将组合物制成片剂,规格为0.4g/片。
实施例5
实施例1-3任一所述的一种中药组合物的制备方法,包括以下步骤:
(1)称取各原料,备用;
(2)将各原料洗净、去除杂质,在66℃下干燥;
(3)将南瓜粉、酸枣仁、芡实、五味子和甘草放入破壁机中,在40000r/min的转速下破壁2min,过100目筛,得细粉A;
(4)将葛根、黄芪、山药、乌梅、沙棘和西洋参放入多功能提取罐中,加11倍量水回流提取2.5h,药渣加9倍水回流提取1.5h,得提取液,然后将提取液经离心机滤过,减压浓缩至在70℃下测定相对密度为1.32的稠膏,在85℃下干燥后,粉碎,过100目筛,得细粉B;
(5)将细粉A、细粉B和葡萄糖酸铬混合均匀,将组合物制成胶囊制剂,规格为0.4g/粒。
实施例6
效用实验:
1.材料与方法
1.1受试者选择
受试者共选用60例,均为II型糖尿病人,男性28例,女性32例,年龄分布为30-49岁24例,50-69岁34例,70岁以上2例。
1.2实验对象分组
将60例实验对象随机分为实验组和对照组,采用双盲法,实验组服用本发明实施例5制备的胶囊,每日三次,每次4-6粒;对照组服用不含葡萄糖酸铬成分的胶囊,其余成分与实施例5制备的胶囊成分相同。每日三次,每次4-6粒;
实验开始前,对所有受试者进行体格检查,同时测定空腹血糖、餐后2小时血糖、尿糖、血清总胆固醇、甘油三酯,血象检查和其它生化学指标检查。实验时间为30天,检查仪器为日立8810全自动生化分析仪。
1.3诊断标准
以WHO糖尿病专家委员会1980年提出的暂行标准为诊断依据,即有糖尿病症状、且空腹血糖值≥7.8mmol/L,定为糖尿病;空腹血糖≤5.7mmol/L,排除糖尿病;空腹血糖介于5.7-7.7mmol/L之间,并且症状不明显,为糖耐量异常或血糖异常。餐后血糖为食用100g精粉馒头后2小时血糖,本发明中的诊断标准为:餐后2h血糖<7.8mmol/L为正常;7.8-11.1mmol/L为糖耐量异常,>11.1mmol/L为糖尿病。
2功效判定
按中华人民共和国卫生部内分泌药物临床研究指导原则(1988年)用血糖变化作为主要判断指标。
①显效:实验期末,症状基本消失;空腹血糖较实验前降低≥30%或2mmol/L以上或降至7.2mmol/L以下,尿糖降至“-”或一个“+”;
②有效:实验期末,症状减轻,空腹血糖较实验前降低≥10%或降至8.3mmol/L以下,尿糖至少下降一个“+”;
③无效:任何一项不符合上述“有效”标准,均为无效。
3实验结果
3.1症状观察
以口渴、多饮、多食、多尿、消瘦、乏力、嗜睡、肢体麻木刺痛等为主要临床症状,并按症状鸡粪(重症3份,中症2份,轻症1份),根据实验前后的统计积分值,计算症状改善率(改善2分为显效,1分为有效,0分为无效),结果见表1
表1临床症状改善率
*与对照组相比x2=15.42P<0.01
上述结果说明,实验组具有明显改善临床症状的功效,其改善率为80%。
3.2辅助调节血糖作用观察
对调节血糖、尿糖作用结果见表2、3和4。
表2对空腹血糖的影响
**与实验前比,t=4.61,P<0.01,差异极显著。
△与实验组实验末比,t=2.12,P<0.05,差异显著。
表3对餐后2h血糖的影响
**与实验前比,t=4.53,P<0.01,差异非常显著。
△与实验组实验末比,t=1.68,P<0.05,差异显著。
表4对尿糖的影响
**与实验前比,μ=5.25,P<0.01,差异极显著。
△与实验组实验末比,μ=2.05,P<0.05,差异显著。
3.3安全性观察
对人体各项生化指标实验检查,结果见表5表5生化指标检验结果
表5结果表明本发明对肝肾功能无任何损害作用。
4.结论
通过30天的观察实验,实验组30人的空腹血糖平均值(mmol/L)由实验前的15.69±4.85下降为10.42±3.96,餐后2h血糖由18.56±4.30降为12.79±5.50,显著低于对照组;尿糖由实验前的80个“+”下降为53个“+”,表明本发明具有降低血糖和尿糖、减轻糖尿病临床症状的保健功效,显效率为30%,有效率为53.3%,累积有效率达83.3%。
对所公开的实施例的上述说明,使本领域专业技术人员能够实现或使用本发明。对这些实施例的多种修改对本领域的专业技术人员来说将是显而易见的,本文中所定义的一般原理可以在不脱离本发明的精神或范围的情况下,在其它实施例中实现。因此,本发明将不会被限制于本文所示的这些实施例,而是要符合与本文所公开的原理和新颖特点相一致的最宽的范围。
Claims (6)
1.一种中药组合物,其特征在于,包括以下重量份的原料:
黄芪32-48份、山药32-48份、西洋参20-30份、南瓜粉20-30份、乌梅20-30份、葛根16-24份、芡实16-24份、沙棘16-24份、五味子16-24份、酸枣仁16-24份、甘草5-9份、葡萄糖酸铬0.04-0.06份。
2.根据权利要求1所述的一种中药组合物,其特征在于,包括以下重量份的原料:
黄芪40份、山药40份、西洋参25份、南瓜粉25份、乌梅25份、葛根20份、芡实20份、沙棘20份、五味子20份、酸枣仁20份、甘草7份、葡萄糖酸铬0.05份。
3.一种中药组合物的制备方法,其特征在于,包括以下步骤:
(1)称取权利要求1-2任一所述各原料,备用;
(2)将各原料洗净、去除杂质,在66-70℃下干燥;
(3)将南瓜粉、酸枣仁、芡实、五味子和甘草破壁处理,过筛,得细粉A;
(4)将葛根、黄芪、山药、乌梅、沙棘和西洋参混合,然后提取,制膏干燥后粉碎,过筛,得细粉B;
(5)将细粉A、细粉B和葡萄糖酸铬混合均匀,按所需剂型制得成品。
4.根据权利要求3所述的中药组合物的制备方法,其特征在于,步骤(3)中所述破壁处理采用破壁机,转速为40000~45000r/min;时间1~2min。
5.根据权利要求3所述的中药组合物的制备方法,其特征在于,步骤(4)中所述提取为将葛根、黄芪、山药、乌梅、沙棘和西洋参放入多功能提取罐中,加11倍量水回流提取2.5-3h,药渣加9倍水回流提取1.5-2h,得提取液。
6.根据权利要求5所述的中药组合物的制备方法,其特征在于,步骤(4)中制膏为将所述提取液经离心机滤过,减压浓缩至在70℃下测定相对密度为1.32-1.34的稠膏,之后在80-85℃条件下干燥。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110865627.3A CN113384644A (zh) | 2021-07-29 | 2021-07-29 | 一种中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110865627.3A CN113384644A (zh) | 2021-07-29 | 2021-07-29 | 一种中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113384644A true CN113384644A (zh) | 2021-09-14 |
Family
ID=77622237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110865627.3A Pending CN113384644A (zh) | 2021-07-29 | 2021-07-29 | 一种中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113384644A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1618446A (zh) * | 2003-11-19 | 2005-05-25 | 王锦刚 | 一种治疗糖尿病的药物及其制备方法 |
CN107243043A (zh) * | 2017-08-17 | 2017-10-13 | 刘明州 | 一种治疗糖尿病和控制其并发症发生的中药 |
-
2021
- 2021-07-29 CN CN202110865627.3A patent/CN113384644A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1618446A (zh) * | 2003-11-19 | 2005-05-25 | 王锦刚 | 一种治疗糖尿病的药物及其制备方法 |
CN107243043A (zh) * | 2017-08-17 | 2017-10-13 | 刘明州 | 一种治疗糖尿病和控制其并发症发生的中药 |
Non-Patent Citations (1)
Title |
---|
侯丽雅 等: "消渴扶正胶囊治疗Ⅱ型糖尿病58例", 《中国中医药科技》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100435831C (zh) | 治疗高血压、高血脂、肥胖症及更年期综合症的制剂及其制备方法 | |
CN113521134A (zh) | 一种用于治疗ii型糖尿病的中药组合物与应用 | |
CN101979020B (zh) | 一种治疗高血压的中药制剂 | |
CN100493572C (zh) | 一种治疗糖尿病的药物组合物 | |
CN101856405B (zh) | 一种治疗2型糖尿病的药物组合物及其制备方法 | |
CN102526345B (zh) | 一种治疗高血压的中药组合物 | |
CN104815166B (zh) | 一种治疗糖尿病的中药组合物及其制备和应用 | |
CN112336802B (zh) | 一种改善糖尿病糖脂代谢的中药组合物及其应用 | |
CN101095768A (zh) | 一种治疗中老年原发性高血压的中药胶囊 | |
CN102218116B (zh) | 治疗糖尿病的中药药物及其制备方法 | |
CN101041047A (zh) | 一种内服治疗慢性浅表性胃炎的中药组合物 | |
CN103735663B (zh) | 一种降血糖中药及其制备方法 | |
CN105999058B (zh) | 鬼针草降脂片 | |
CN101843843A (zh) | 一种治疗糖尿病的中药 | |
CN105769957B (zh) | 一种雪梨米泔水制三七粉及其制剂和制备方法 | |
CN113384644A (zh) | 一种中药组合物及其制备方法 | |
CN100388945C (zh) | 三七脂肝制剂及其制备方法 | |
CN105343675A (zh) | 一种治疗肥胖症的中药制剂及其制备方法 | |
CN104800600A (zh) | 一种治疗高血压的药物 | |
CN104324134A (zh) | 一种改善微循环的中药组合物及其制备方法 | |
CN102100853B (zh) | 一种治疗痛风的中药及其制备方法 | |
CN108403803B (zh) | 一种防治糖尿病心血管并发症的中药复方制剂 | |
CN106668390B (zh) | 一种治疗早中期甲状腺功能亢进症的中药组合物 | |
CN113577202A (zh) | 治疗糖尿病的铁皮石斛组合物及其制备方法和应用 | |
CN110123939A (zh) | 治疗心绞痛合并2型糖尿病的中药组合物及制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210914 |
|
WD01 | Invention patent application deemed withdrawn after publication |